Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ondine Biomedical, Inc. ( (GB:OBI) ) has provided an announcement.
Royal Columbian Hospital Foundation’s Advancing Innovation in Medicine team has published a landmark ICU feasibility pilot study showing that Ondine Biomedical’s Steriwave nasal photodisinfection achieved a 39.5% reduction in pneumonia rates, from 14.9 to 9.0 cases per 1,000 ICU patient-days. While not powered for definitive clinical outcomes, the study reported a statistically significant drop in early nasal pathogen burden with no intervention-related adverse events, laying the groundwork for larger, multicentre trials.
Researchers say a simple five-minute nasal treatment could materially cut ventilator-associated and other nosocomial pneumonias, which are linked to longer ICU stays, higher mortality and tens of thousands of dollars in added costs per case. The findings underscore the potential of broad-spectrum photodisinfection, which remains effective against multidrug-resistant Gram-negative bacteria increasingly responsible for ICU infections, to reshape ICU infection-prevention protocols and ease capacity and cost pressures on strained health systems.
Spark’s Take on OBI Stock
According to Spark, TipRanks’ AI Analyst, OBI is a Underperform.
Ondine Biomedical, Inc. receives a low overall score due to significant financial performance challenges, bearish technical indicators, and unattractive valuation metrics. The company’s strong revenue growth is overshadowed by its inability to achieve profitability and positive cash flow, while technical analysis suggests continued negative momentum.
To see Spark’s full report on OBI stock, click here.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specialising in light-activated antimicrobial therapies, known as photodisinfection, for preventing and treating infections, including those caused by multidrug-resistant organisms. Its flagship Steriwave nasal photodisinfection system is approved in multiple countries for nasal decolonisation and is in U.S. clinical trials, alongside a pipeline targeting indications such as chronic sinusitis, ventilator-associated pneumonia and burns.
Average Trading Volume: 227,356
Technical Sentiment Signal: Sell
Current Market Cap: £57.02M
Find detailed analytics on OBI stock on TipRanks’ Stock Analysis page.